Immunoglobulin G4-related disease and B-cell malignancy due to an IKZF1 gain-of-function variant
CONCLUSION: Heterozygosity for gain-of-function IKZF1 variants underlies autoimmunity/inflammatory diseases, IgG4-RD and B-cell malignancies, the onset of which may occur in adulthood. Clinical and immunological data are similar to those for patients with unexplained IgG4-RD. Patients may therefore benefit from treatments inhibiting pathways displaying IKAROS-mediated overactivity.PMID:38579942 | DOI:10.1016/j.jaci.2024.03.018 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 5, 2024 Category: Cancer & Oncology Authors: Blanca Garc ía-Solís Mar ía Tapia-Torres Ana Garc ía-Soidán Elisa Hern ández-Brito Mar ía Teresa Martínez-Saavedra Jos é M Lorenzo Salazar Sonia Garc ía-Hernández Ana Van Den Rym Karan Mayani Mayani Jos é Vicente Govantes-Rodríguez Adrian Ger Source Type: research
Prevalence and Consequences of a Delayed Diagnosis in Multiple Myeloma: A Single Institution Experience
CONCLUSION: A delay in the diagnosis of MM is very frequent in México (68% of cases); despite the fact that there was a significant trend for being in earlier stages of the disease and being diagnosed within 3 months from the onset of symptoms, we did not find a relationship between a delay on the diagnosis of the disease and a higher risk of complications and/or poor prognosis. Possible explanations to these findings are discussed.PMID:38555259 | DOI:10.1016/j.clml.2024.03.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 30, 2024 Category: Cancer & Oncology Authors: Paola Negrete-Rodr íguez Mois és Manuel Gallardo-Pérez Olivia Lira-Lara Miranda Melgar-de-la-Paz Luis Enrique Hamilton-Avil és Guillermo Oca ña-Ramm Max Robles-Nasta Daniela S ánchez-Bonilla Juan Carlos Olivares-Gazca Mar ía-Victoria Mateos Guiller Source Type: research
Prevalence and Consequences of a Delayed Diagnosis in Multiple Myeloma: A Single Institution Experience
CONCLUSION: A delay in the diagnosis of MM is very frequent in México (68% of cases); despite the fact that there was a significant trend for being in earlier stages of the disease and being diagnosed within 3 months from the onset of symptoms, we did not find a relationship between a delay on the diagnosis of the disease and a higher risk of complications and/or poor prognosis. Possible explanations to these findings are discussed.PMID:38555259 | DOI:10.1016/j.clml.2024.03.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 30, 2024 Category: Cancer & Oncology Authors: Paola Negrete-Rodr íguez Mois és Manuel Gallardo-Pérez Olivia Lira-Lara Miranda Melgar-de-la-Paz Luis Enrique Hamilton-Avil és Guillermo Oca ña-Ramm Max Robles-Nasta Daniela S ánchez-Bonilla Juan Carlos Olivares-Gazca Mar ía-Victoria Mateos Guiller Source Type: research
Prevalence and Consequences of a Delayed Diagnosis in Multiple Myeloma: A Single Institution Experience
CONCLUSION: A delay in the diagnosis of MM is very frequent in México (68% of cases); despite the fact that there was a significant trend for being in earlier stages of the disease and being diagnosed within 3 months from the onset of symptoms, we did not find a relationship between a delay on the diagnosis of the disease and a higher risk of complications and/or poor prognosis. Possible explanations to these findings are discussed.PMID:38555259 | DOI:10.1016/j.clml.2024.03.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 30, 2024 Category: Cancer & Oncology Authors: Paola Negrete-Rodr íguez Mois és Manuel Gallardo-Pérez Olivia Lira-Lara Miranda Melgar-de-la-Paz Luis Enrique Hamilton-Avil és Guillermo Oca ña-Ramm Max Robles-Nasta Daniela S ánchez-Bonilla Juan Carlos Olivares-Gazca Mar ía-Victoria Mateos Guiller Source Type: research
Prevalence and Consequences of a Delayed Diagnosis in Multiple Myeloma: A Single Institution Experience
CONCLUSION: A delay in the diagnosis of MM is very frequent in México (68% of cases); despite the fact that there was a significant trend for being in earlier stages of the disease and being diagnosed within 3 months from the onset of symptoms, we did not find a relationship between a delay on the diagnosis of the disease and a higher risk of complications and/or poor prognosis. Possible explanations to these findings are discussed.PMID:38555259 | DOI:10.1016/j.clml.2024.03.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 30, 2024 Category: Cancer & Oncology Authors: Paola Negrete-Rodr íguez Mois és Manuel Gallardo-Pérez Olivia Lira-Lara Miranda Melgar-de-la-Paz Luis Enrique Hamilton-Avil és Guillermo Oca ña-Ramm Max Robles-Nasta Daniela S ánchez-Bonilla Juan Carlos Olivares-Gazca Mar ía-Victoria Mateos Guiller Source Type: research
Prevalence and Consequences of a Delayed Diagnosis in Multiple Myeloma: A Single Institution Experience
CONCLUSION: A delay in the diagnosis of MM is very frequent in México (68% of cases); despite the fact that there was a significant trend for being in earlier stages of the disease and being diagnosed within 3 months from the onset of symptoms, we did not find a relationship between a delay on the diagnosis of the disease and a higher risk of complications and/or poor prognosis. Possible explanations to these findings are discussed.PMID:38555259 | DOI:10.1016/j.clml.2024.03.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 30, 2024 Category: Cancer & Oncology Authors: Paola Negrete-Rodr íguez Mois és Manuel Gallardo-Pérez Olivia Lira-Lara Miranda Melgar-de-la-Paz Luis Enrique Hamilton-Avil és Guillermo Oca ña-Ramm Max Robles-Nasta Daniela S ánchez-Bonilla Juan Carlos Olivares-Gazca Mar ía-Victoria Mateos Guiller Source Type: research
SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?
Clin Lymphoma Myeloma Leuk. 2024 Mar 6:S2152-2650(24)00093-4. doi: 10.1016/j.clml.2024.02.015. Online ahead of print.ABSTRACTHistorically, therapeutic clinical trials in myelofibrosis have predominantly focused on targeting patients with higher-risk disease who are at risk of increased morbidity and mortality. The endpoints have been designed to target regularly measured disease parameters that are of immediate pertinence to patient's welfare including splenic volume reduction and symptom reduction. These efforts have resulted in meaningful and measurable improvements in disease parameters in these high-risk study populati...
Source: Clinical Lymphoma and Myeloma - March 29, 2024 Category: Cancer & Oncology Authors: Abdulraheem Yacoub Nicole Twardowski Alec Britt Nour Shraim Source Type: research
SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?
Clin Lymphoma Myeloma Leuk. 2024 Mar 6:S2152-2650(24)00093-4. doi: 10.1016/j.clml.2024.02.015. Online ahead of print.ABSTRACTHistorically, therapeutic clinical trials in myelofibrosis have predominantly focused on targeting patients with higher-risk disease who are at risk of increased morbidity and mortality. The endpoints have been designed to target regularly measured disease parameters that are of immediate pertinence to patient's welfare including splenic volume reduction and symptom reduction. These efforts have resulted in meaningful and measurable improvements in disease parameters in these high-risk study populati...
Source: Clinical Lymphoma and Myeloma - March 29, 2024 Category: Cancer & Oncology Authors: Abdulraheem Yacoub Nicole Twardowski Alec Britt Nour Shraim Source Type: research
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
CONCLUSION: TN-MF is invariably associated with significantly decreased survival and more aggressive clinical behavior with higher rates of leukemic transformation and shorter duration of response to ruxolitinib. Mutations impacting RNA splicing, epigenetic modification and signaling (SRSF2, SETBP1, IDH2, CBL, and GNAS) are more common in TN-MF, which likely drive its aggressive course and may account for suboptimal responses to JAK inhibition.PMID:38548563 | DOI:10.1016/j.clml.2024.03.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 28, 2024 Category: Cancer & Oncology Authors: Luis E Aguirre Akriti Jain Somedeb Ball Najla Al Ali Virginia O Volpe Sara Tinsley-Vance David Sallman Kendra Sweet Jeffrey Lancet Eric Padron Seongseok Yun Andrew Kuykendall Rami Komrokji Source Type: research
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
CONCLUSION: TN-MF is invariably associated with significantly decreased survival and more aggressive clinical behavior with higher rates of leukemic transformation and shorter duration of response to ruxolitinib. Mutations impacting RNA splicing, epigenetic modification and signaling (SRSF2, SETBP1, IDH2, CBL, and GNAS) are more common in TN-MF, which likely drive its aggressive course and may account for suboptimal responses to JAK inhibition.PMID:38548563 | DOI:10.1016/j.clml.2024.03.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 28, 2024 Category: Cancer & Oncology Authors: Luis E Aguirre Akriti Jain Somedeb Ball Najla Al Ali Virginia O Volpe Sara Tinsley-Vance David Sallman Kendra Sweet Jeffrey Lancet Eric Padron Seongseok Yun Andrew Kuykendall Rami Komrokji Source Type: research
SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia
We present our approach to newly diagnosed patients with B-ALL and illustrate how the incorporation of novel agents and use of high-sensitivity MRD assays can abrogate the need for allo-SCT in most patients with B-ALL.PMID:38538495 | DOI:10.1016/j.clml.2024.02.017 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 27, 2024 Category: Cancer & Oncology Authors: Wei-Ying Jen Elias Jabbour Hagop M Kantarjian Nicholas J Short Source Type: research
Are the GLIM Criteria Guiding in the Course of Hematological Malignancies?
CONCLUSION: Early nutritional support can increase the immunological status of patients with malignant disorders as well as their tolerability to treatment. Minimizing the risk of malnutrition and providing timely calorie and vitamin support are factors that may directly affect febrile neutropenia, duration of fever, and antifungal use, which will consequently lead to a decrease in the length of hospitalization.PMID:38528354 | DOI:10.4103/njcp.njcp_572_23 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2024 Category: Cancer & Oncology Authors: F Yilmaz M R Aras Hba Ozturk H N Sahin A K Gunes M Albayrak Source Type: research
Are the GLIM Criteria Guiding in the Course of Hematological Malignancies?
CONCLUSION: Early nutritional support can increase the immunological status of patients with malignant disorders as well as their tolerability to treatment. Minimizing the risk of malnutrition and providing timely calorie and vitamin support are factors that may directly affect febrile neutropenia, duration of fever, and antifungal use, which will consequently lead to a decrease in the length of hospitalization.PMID:38528354 | DOI:10.4103/njcp.njcp_572_23 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2024 Category: Cancer & Oncology Authors: F Yilmaz M R Aras Hba Ozturk H N Sahin A K Gunes M Albayrak Source Type: research
Are the GLIM Criteria Guiding in the Course of Hematological Malignancies?
CONCLUSION: Early nutritional support can increase the immunological status of patients with malignant disorders as well as their tolerability to treatment. Minimizing the risk of malnutrition and providing timely calorie and vitamin support are factors that may directly affect febrile neutropenia, duration of fever, and antifungal use, which will consequently lead to a decrease in the length of hospitalization.PMID:38528354 | DOI:10.4103/njcp.njcp_572_23 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2024 Category: Cancer & Oncology Authors: F Yilmaz M R Aras Hba Ozturk H N Sahin A K Gunes M Albayrak Source Type: research
Dampening Logistics Creating Inequitable Access: A Major Threat Despite Advancements
Clin Lymphoma Myeloma Leuk. 2024 Feb 22:S2152-2650(24)00083-1. doi: 10.1016/j.clml.2024.02.011. Online ahead of print.NO ABSTRACTPMID:38521639 | DOI:10.1016/j.clml.2024.02.011 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 23, 2024 Category: Cancer & Oncology Authors: Fathima Shehnaz Ayoobkhan Al-Ola Abdallah Faiz Anwer Nausheen Ahmed Source Type: research
